* Vabysmo shows better drying in patients with nAMD or DME (in nAMD related to greater reduction in CST during initial loading phase, in DME stronger CST reductions over 2 years) and faster drying (first absence of CST or IRF) vs. aflibercept.

References:

1. Lim, J et al. Extended Dosing of Faricimab in the Phase 3 YOSEMITE/RHINE and TENAYA/LUCERNE Trials, Presented at the Macula Society 47th Annual Meeting, Palm Springs, CA, February 7–10, 2024
2. Lim, J. et al. Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME, Pre- sented at Angiogenesis Virtual Congress, February 3, 2024,
3. VABYSMO® Information for healthcare professionals at www.swissmedicinfo.ch
4. Information on Swiss drug prices as per https://www.xn-spezialittenliste-yqb.ch/ShowPreparations.aspx (08.06.2023).
5. Penha, F. et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitr 10, 5 (2024). https://doi.org/10.1186/s40942-024-00525-9.
6. Khanani Arshad M. et al. Faricimab in nAMD and DME: Latest Updates Presented at the Angiogenesis, Exudation, and Degeneration 2023 Virtual Congress. February 10–11, 2023.
7. SAP Harvest Report Roche Pharma (Schweiz) AG 02/2024

All references listed in this document can be requested by healthcare professionals from Roche Pharma (Switzerland) Ltd.

VABYSMO® (Faricimab)

▼ This medicinal product is subject to additional monitoring. For more information, see Vabysmo Information for healthcare professionals at www.swissmedicinfo.ch

VABYSMO® (Faricimab) I: Treatment of 1) neovascular (wet) age-related macular degeneration (nAMD) and 2) diabetic macular oedema (DMO). D: Loading dose: 4 intravitreal (IVT) injections of 6 mg every 4 weeks, followed by 6 mg IVT at intervals up to a maximum of 16 weeks, based on visual acuity and morphology. CI: Hypersensitivity to faricimab or any of the excipients, ocular or periocular infection, active intraocular inflammation. Prc: Reactions to IVT injection (endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear, retinal pigment epithelial tear): Patients should be instructed to report symptoms such as pain, vision loss, photophobia, blurred vision, vitreous floaters or redness without delay. Aseptic injection techniques must always be used. Particular caution is required in patients with inadequately treated glaucoma. Vabysmo must not be injected if the IOP is ≥30 mmHg. Monitor intraocular pressure, optic disc perfusion and/or vision. Immunogenicity: Patients should be instructed to report any signs or symptoms of intraocular inflammation. Suspend treatment in the event of rhegmatogenous retinal detachment, macular hole, retinal tear, treatment-related reduction in BCVA, intraocular surgery performed or planned within +/- 28 days. Retinal pigment epithelial tear: Caution when initiating treatment due to potential for pigment epithelial detachment. Systemic events: Potential risk of systemic effects including arterial thromboembolic events during IVT treatment with VEGF inhibitors. IA: No interaction studies have been performed with Vabysmo. P&L: There are no data on the use of Vabysmo in pregnant women. It is not known if Vabysmo is excreted in human milk. AE: Serious adverse effects related to the IVT procedure: cataract, uveitis, endophthalmitis, vitritis, retinal tear and rhegmatogenous retinal detachment. Commonest adverse effect: cataract, conjunctival haemorrhage, intraocular pressure increased, vitreous opacities, eye pain and retinal pigment epithelial tear (nAMD only). P: Each 0.24 ml vial contains 28.8 mg faricimab. Dispensing category: B. For further information, please see the Information for healthcare professionals at www.swissmedicinfo.ch. Status: Januar 2024.
Roche Pharma (Switzerland) Ltd • Grenzacherstrasse 124 • 4058 Basel

M-CH-00004054                 03/2024                Roche Pharma (Switzerland) Ltd • Grenzacherstrasse 124 • 4058 Basel